<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" dms-id="H8FA39E24CD35473BA4D6FDBC5B4D3EB3" public-private="public" key="H" bill-type="olc"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>119 HR 4299 IH: Protecting Patient Access to Cancer and Complex Therapies Act</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2025-07-07</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">119th CONGRESS</congress><session display="yes">1st Session</session><legis-num display="yes">H. R. 4299</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20250707">July 7, 2025</action-date><action-desc><sponsor name-id="M001210">Mr. Murphy</sponsor> (for himself, <cosponsor name-id="G000605">Mr. Gray</cosponsor>, and <cosponsor name-id="D000628">Mr. Dunn of Florida</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name>, and in addition to the Committee on <committee-name committee-id="HWM00">Ways and Means</committee-name>, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned</action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To amend title XVIII of the Social Security Act to provide for a rebate by manufacturers for selected drugs and biological products subject to maximum fair price negotiation.</official-title></form><legis-body id="HA146844B81F947188B7D502C12C1F557" style="OLC"><section section-type="section-one" id="H3B61B9371F2543EA9E304F7A031934BE"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Protecting Patient Access to Cancer and Complex Therapies Act</short-title></quote>.</text></section><section id="H0908A2B89E9E4D36AFD9CFDE80D06E57"><enum>2.</enum><header>Rebate by manufacturers for selected drugs and biological products subject to maximum fair price negotiation</header><subsection id="HE8273F608DC04AF6A13E869DEE9F6C3B"><enum>(a)</enum><header>Maintaining payments under part B based on ASP+6</header><text display-inline="yes-display-inline">Section 1847A(b)(1)(B) of the Social Security Act (42 U.S.C. 1395w–3a(b)(1)(B)) is amended by striking <quote>or in the case of such a drug or biological product that is a selected drug</quote> and all that follows through the semicolon and inserting a semicolon.</text></subsection><subsection id="H6FACA6C74A52402097358134CD71FB52"><enum>(b)</enum><header>Rebate by manufacturers for selected drugs and biological products subject to maximum fair price negotiation</header><paragraph id="HFF763D77B52D4D699475E964DC0AA63C"><enum>(1)</enum><header>In general</header><text>Section 1847A of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395w-3a">42 U.S.C. 1395w–3a</external-xref>) is amended—</text><subparagraph id="H1BAF796FE4AA465AA16B50A0E4A22CE2"><enum>(A)</enum><text>by redesignating subsection (j) as subsection (k); and</text></subparagraph><subparagraph id="H25EE3C7DF86940DEB5BB3A7C193D3DCF"><enum>(B)</enum><text>by inserting after subsection (i) the following new subsection:</text><quoted-block style="OLC" display-inline="no-display-inline" id="H0D95A450408C4F28B3F9528826052A68"><subsection id="HE793782C1574446DBECA154471D4907C"><enum>(j)</enum><header>Rebate by manufacturers for selected drugs and biological products subject to maximum fair price negotiation</header><paragraph id="H7453C3DEB97E4198B02708164377B110"><enum>(1)</enum><header>Requirements</header><subparagraph id="HAF606F1BA43C448EA481494DC0C9CE72"><enum>(A)</enum><header>Secretarial provision of information</header><text>Not later than 6 months after the end of each calendar quarter beginning on or after the first day of the initial price applicability period (as defined in section 1191(b)(2)), the Secretary shall, for each selected drug (as defined in section 1192(c)) of each manufacturer with an agreement under section 1193 for which a maximum fair price is in effect and for which payment may be made under this part, report to each manufacturer of such selected drug the following for such calendar quarter during such price applicability period:</text><clause id="HD00BEA242DE0460296925C45DD40D404"><enum>(i)</enum><text>Information on the total number of units of the billing and payment code for such selected drug furnished under this part during such calendar quarter.</text></clause><clause id="HB1426CD950474908ACBB4C15EF018533"><enum>(ii)</enum><text>Information on the sum of—</text><subclause id="H31A05535D8AB42A7AE1483625BF7B2D0"><enum>(I)</enum><text>the amount (if any) by which—</text><item id="H4BAD101ABA304FD39279A39B7DF2CA9F"><enum>(aa)</enum><text>the ASP+6 payment amount (as defined in paragraph (5)) for such drug and calendar quarter, less the ASP+6 coinsurance amount for such drug and calendar quarter; exceeds</text></item><item id="H327BC948CE1A45849338FF480D47298F"><enum>(bb)</enum><text>the MFP+6 payment amount (as so defined) for such drug and calendar quarter, less the MFP+6 coinsurance amount for such drug and calendar quarter; and</text></item></subclause><subclause id="H377B3B69D7904B989F1CAA701FAF11C0"><enum>(II)</enum><text>the amount (if any) by which—</text><item id="H5EDCE454D47E45A397168C944E2ECB04"><enum>(aa)</enum><text>the ASP+6 coinsurance amount (as defined in paragraph (5)) for such drug and calendar quarter; exceeds</text></item><item id="H92D46DBA97C74566A11059147F9D8DED"><enum>(bb)</enum><text>the MFP+6 coinsurance amount (as so defined) for such drug and calendar quarter.</text></item></subclause></clause><clause id="H787F739E43AE48D3B7B3AF7CDD47C597"><enum>(iii)</enum><text>The rebate amount specified under subparagraph (B) for such drug and calendar quarter.</text></clause></subparagraph><subparagraph id="H26D0959657EF4D05B457853A40D9DC75"><enum>(B)</enum><header>Manufacturer requirement</header><text>For each calendar quarter beginning on or after the first day of the initial price applicability period (as defined in section 1191(b)(2)), the manufacturer of a selected drug shall, for such drug, not later than 30 days after the date of receipt from the Secretary of the information described in subparagraph (A) for such calendar quarter, provide to the Secretary a rebate that is equal to the amount specified in subparagraph (A)(ii) multiplied by the number of units specified in subparagraph (A)(i) for such drug for such calendar quarter. The rebate required under this subparagraph shall be in addition to any other rebates required under this title or title XIX, including the payments required under subsections (h) and (i).</text></subparagraph></paragraph><paragraph id="H58E35EFCF65F4F0BB1AB892B9A7932CE"><enum>(2)</enum><header>Calculation of beneficiary coinsurance based on mfp+6</header><subparagraph id="HDF656B0B227342B7B424EE4C9E3D7FF7"><enum>(A)</enum><header>In general</header><text>Subject to subparagraph (B), in the case of a selected drug with respect to which a rebate is paid under this subsection—</text><clause id="H986F3D05C0BB4DBB8F14BCCC5797AA29"><enum>(i)</enum><text>the amount of any coinsurance applicable under this part to an individual to whom such drug is furnished during a calendar quarter shall be equal to the MFP+6 coinsurance amount; and</text></clause><clause id="H7B8EF16C9C8145748DDA94DA087626DD"><enum>(ii)</enum><text display-inline="yes-display-inline">the amount of such coinsurance for such calendar quarter shall be applied as a percent, as determined by the Secretary, to the payment amount that would otherwise apply under subsection (b)(1)(B).</text></clause></subparagraph><subparagraph commented="no" id="HBA494D7CF77C48FAAEDC44062768D1DB"><enum>(B)</enum><header>Clarification regarding application of inflation rebate</header><text>If a rebate is required under subsection (i) with respect to a selected drug for a calendar quarter, the lesser of the amount of coinsurance computed under subparagraph (A) or the coinsurance computed under subsection (i)(5) shall apply for such drug and calendar quarter.</text></subparagraph></paragraph><paragraph id="H22081F73D94A4A5BAA7480327AE4FF56"><enum>(3)</enum><header>Rebate deposits</header><text>Amounts paid as rebates under paragraph (1)(B) shall be deposited into the Federal Supplementary Medical Insurance Trust Fund established under section 1841.</text></paragraph><paragraph id="H89F7E9B59AE248819473BE70240C562A"><enum>(4)</enum><header>Civil money penalty</header><text>The civil money penalty established under paragraph (7) of subsection (i) shall apply to the failure to comply with this subsection in the same manner as such penalty applies to failures to comply with the requirements under paragraph (1)(B) of subsection (i).</text></paragraph><paragraph id="HCA8BA5E1841842179979F2DBE74A3CFF"><enum>(5)</enum><header>Definitions</header><text>In this subsection, with respect to a selected drug for a calendar quarter during a price applicability period:</text><subparagraph id="H8C250232A9024645A9219242F08F917D"><enum>(A)</enum><header>ASP+6 coinsurance amount</header><text>The <term>ASP+6 coinsurance amount</term> is equal to 20 percent of the ASP+6 payment amount.</text></subparagraph><subparagraph id="H1889F80FFB31495C90A9B30D21F826CF"><enum>(B)</enum><header>ASP+6 payment amount</header><text>The <term>ASP+6 payment amount</term> is equal to 106 percent of the amount determined under paragraph (4) of subsection (b) for such drug during such calendar quarter.</text></subparagraph><subparagraph id="HCCCDA5B3E497468487A2B5280D613718"><enum>(C)</enum><header>MFP+6 coinsurance amount</header><text>The <term>MFP+6 coinsurance amount</term> is equal to 20 percent of the MFP+6 payment amount.</text></subparagraph><subparagraph id="HDB5379E131BA49E8BF83CB5DDF2605B1"><enum>(D)</enum><header>MFP+6 payment amount</header><text>The <term>MFP+6 payment amount</term> is equal to 106 percent of the maximum fair price (as defined in section 1191(c)(2)) applicable for such drug during such calendar quarter.</text></subparagraph></paragraph><paragraph id="HB4557001EF3C4521B8D043A97D9C42E4" commented="no"><enum>(6)</enum><header>Clarification</header><text>Nothing in part E of title XI or this subsection shall be construed to require a manufacturer to provide selected drugs at maximum fair prices other than through the rebate required under this subsection. </text></paragraph></subsection><after-quoted-block>.</after-quoted-block></quoted-block></subparagraph></paragraph><paragraph id="H8938B62BDCAC41FDBA0517D7B2832BA7"><enum>(2)</enum><header>Amounts payable; cost-sharing</header><text>Section 1833(a)(1) of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395l">42 U.S.C. 1395l(a)(1)</external-xref>) is amended—</text><subparagraph id="H9A3304570DD747349256C9B010D68F83"><enum>(A)</enum><text>in subparagraph (G), by striking <quote>subsection (i)(9)</quote> and inserting <quote>paragraphs (9) and (10) of subsection (i)</quote>;</text></subparagraph><subparagraph id="HB9861B70886A4646B6B267F5DD50FF66"><enum>(B)</enum><text>in subparagraph (S), by striking <quote>subparagraph (EE)</quote> and inserting <quote>subparagraphs (EE) and (II)</quote>;</text></subparagraph><subparagraph id="H68217D319108492B95BAAD67ECDAD4D9"><enum>(C)</enum><text>by striking <quote>and (HH)</quote> and inserting <quote>(HH)</quote>; and</text></subparagraph><subparagraph id="HE6308899F6924DD683BA9E10937FB378"><enum>(D)</enum><text>by inserting before the semicolon at the end the following: <quote>, and (II) with respect to a selected drug (as defined in section 1192(c)) that is subject to a rebate under section 1847A(j), the amounts paid shall be equal to the percent of the payment amount otherwise determined under section 1847A(b)(1)(B) that equals the difference between (i) 100 percent, and (ii) the percent applied under section 1847A(j)(2)(A)(ii)</quote>.</text></subparagraph></paragraph><paragraph id="H33A7194C272D4EDAA2AAE4EEEC92F99E"><enum>(3)</enum><header>ASC conforming amendments</header><text>Section 1833(i) of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395l">42 U.S.C. 1395l(i)</external-xref>) is amended by adding at the end the following new paragraph:</text><quoted-block style="OLC" display-inline="no-display-inline" id="H00ED77C42EE5487F94F7ABC657ED3D51"><paragraph id="H42999733B53941C1A0D78664C060347F"><enum>(11)</enum><text>In the case of a selected drug (as defined in section 1192(c)), subject to a rebate under section 1847A(j) for which payment under this subsection is not packaged into a payment for a service furnished on or after the initial price applicability year for the selected drug under the revised payment system under this subsection, in lieu of calculation of coinsurance and the amount of payment otherwise applicable under this subsection, the provisions of section 1847(j)(2) and paragraph (1)(II) of subsection (a), shall, as determined appropriate by the Secretary, apply under this subsection in the same manner as such provisions of section 1847A(j)(2) and subsection (a) apply under such section and subsection.</text></paragraph><after-quoted-block>.</after-quoted-block></quoted-block></paragraph><paragraph id="H5FC83765171B4D5EB79D77830D427B68"><enum>(4)</enum><header>Opps conforming amendment</header><text>Section 1833(t)(8) of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395l">42 U.S.C. 1395l(t)(8)</external-xref>) is amended by adding at the end the following new subparagraph:</text><quoted-block style="OLC" display-inline="no-display-inline" id="H1267058628684D7C9507ED2850C50A6C"><subparagraph id="HDAA73627F54A45A1BFFECF4349E39304"><enum>(G)</enum><header>Selected drugs subject to rebate</header><text>In the case of a selected drug (as defined in section 1192(c)), subject to a rebate under section 1847A(j) for which payment under this subsection is not packaged into a payment for a covered OPD service (or group of services) furnished on or after the initial price applicability year for the selected drug, and the payment for such drug is the same as the amount for a calendar quarter under section 1847A(b)(1)(B), under the system under this subsection, in lieu of the calculation of the copayment amount and the amount otherwise applicable under this subsection (other than the application of the limitation described in subparagraph (C)), the provisions of section 1847A(j)(2) and paragraph (1)(II) of subsection (a), shall, as determined by the Secretary apply under this section in the same manner as such provisions of section 1847A(j)(2) and subsection (a) apply under such section and subsection.</text></subparagraph><after-quoted-block>.</after-quoted-block></quoted-block></paragraph><paragraph id="H0B89AFF74D004B8CAD87B5AFBACE2E9D"><enum>(5)</enum><header>Exclusion of selected drug mfp rebates from asp calculation</header><text>Section 1847A(c)(3) of the Social Security Act (42 U.S.C. 1395w–3a(c)(3)) is amended by striking <quote>subsection (i)</quote> and inserting <quote>subsection (i), subsection (j)</quote>.</text></paragraph><paragraph id="H3BAC8340FFBF4116999F0E574E99A19D"><enum>(6)</enum><header>Coordination with medicaid rebate information disclosures</header><text>Section 1927(b)(3)(D)(i) of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1396r-8">42 U.S.C. 1396r–8(b)(3)(D)(i)</external-xref>) is amended by striking <quote>and the rebate</quote> and inserting <quote>and the rebates</quote>.</text></paragraph><paragraph id="H591A3466F05645D9BA744995136C48AC"><enum>(7)</enum><header>Provision of rebates</header><text>Section 1193(a) of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1320f-2">42 U.S.C. 1320f–2(a)</external-xref>) is amended—</text><subparagraph id="HEB543B8FE90B41C5A83FC7664926100D"><enum>(A)</enum><text>in paragraph (1), by striking subparagraph (B) and inserting the following:</text><quoted-block style="OLC" display-inline="no-display-inline" id="H97F9534EABC4467D98F9E53BFFDD58F3"><subparagraph id="H67F49449F04E44F4A57B55E25730F959"><enum>(B)</enum><text>by paying rebates in accordance with section 1847A(j);</text></subparagraph><after-quoted-block>;</after-quoted-block></quoted-block></subparagraph><subparagraph id="HB3610E59EEFA4B1A8A7592F747F222AA"><enum>(B)</enum><text>in paragraph (2), by striking subparagraph (B) and inserting the following:</text><quoted-block style="OLC" display-inline="no-display-inline" id="H032164FA0EDD48FF98B1148B2988D33B"><subparagraph id="HA15DFC875AD94D049704F327B428F895"><enum>(B)</enum><text>by paying rebates in accordance with section 1847A(j);</text></subparagraph><after-quoted-block>; and</after-quoted-block></quoted-block></subparagraph><subparagraph id="HBBAD3AE1FF18424192ED433D1D838CAD"><enum>(C)</enum><text>in paragraph (3), by striking subparagraph (B) and inserting the following:</text><quoted-block style="OLC" display-inline="no-display-inline" id="HAA74010EDCE34F18B042F5B268A9638E"><subparagraph id="HEF0B520417F04FBF8C91298893C5035C"><enum>(B)</enum><text>by paying rebates in accordance with section 1847A(j);</text></subparagraph><after-quoted-block>.</after-quoted-block></quoted-block></subparagraph></paragraph></subsection><subsection id="H1900E9E9F16F4B998186717DF0CCD90B"><enum>(c)</enum><header>Conforming amendments</header><paragraph id="H401D8C6B0F8540BA8A93FA8C6E44B3A0"><enum>(1)</enum><text>Section 1847A(i)(5) of the Social Security Act (42 U.S.C. 1395w–3a(i)(5)) is amended, in the matter preceding subparagraph (A)—</text><subparagraph id="HDE85A2E97C1947D6B10171491577372C"><enum>(A)</enum><text>by striking <quote>In the case</quote> and inserting <quote>Subsection to subsection (j)(2)(B), in the case</quote>; and</text></subparagraph><subparagraph id="HC5373F47EC9942F9A060FD7945D538D1"><enum>(B)</enum><text>by striking <quote>(or, in the case of a part B rebatable drug that is a selected drug (as defined in section 1192(c)), the payment amount described in subsection (b)(1)(B) for such drug)</quote>; and</text></subparagraph></paragraph><paragraph id="H1B2735F3EA4D4709865D9A15799EDA09"><enum>(2)</enum><text>Section 1833(a)(1)(EE) of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395l">42 U.S.C. 1395l(a)(1)(EE)</external-xref>) is amended—</text><subparagraph id="H824507D5DB98497D8B7B27899D1A7CF0"><enum>(A)</enum><text>by striking <quote>(or, in the case of a part B rebatable drug that is a selected drug (as defined in section 1192(c) for which, the payment amount described in section 1847A(b)(1)(B)) for such drug for such quarter</quote>; and</text></subparagraph><subparagraph id="H63DFACD5B817437B8555A6B26D07582B"><enum>(B)</enum><text>by striking <quote>or section 1847A(b)(1)(B), as applicable,</quote>.</text></subparagraph></paragraph></subsection></section></legis-body></bill> 

